Page 22 - 2020-2021-Heroes-Program-Bklt-v1_fa_Neat
P. 22
Philip Sher
Philip M. Sher obtained a Ph.D. in Organic Chemistry at Columbia University. At Bristol-Myers Squibb,
he contributed to the discovery of dapagliflozin, and beta 3 adrenergic agonists and a thromboxane
antagonist tested clinically. He transitioned to medical writing with Novo Nordisk and is now
Senior Manager/Medical Writer with Acadia Pharmaceuticals.
William Washburn
William Washburn received his chemistry training at Princeton, Columbia and Harvard. He taught
at UC Berkeley and worked at Eastman Kodak prior to joining Bristol-Myers Squibb as a Senior
Research Fellow where he led drug discovery programs. This effort produced dapagliflozin which is
marketed for diabetes worldwide as Farxiga®/Forxiga®.
Gang Wu
Gang Wu graduated with an M.S. degree in Organic Chemistry from SUNY at Albany in 1991.
He then joined Sterling Winthrop Company as a process chemist. He has been with BMS since 1995
and is currently a Principal Scientist in the CV and Fibrosis Chemistry group.
22 #HeroesofChemistry
